Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.32 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | KMT5B | Q4FZB7 | 1/20 | 0.30 |
| ▸ | KMT5C | Q86Y97 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7069732 | 0.99 | KMT2A (0.35) | HTR5AMEN1KMT2AABCC8KCNJ11 | |
| SCHEMBL7071984 | 0.97 | HTR5A (0.37) | HTR5AMEN1KMT2AABCC8KCNJ11 | |
| SCHEMBL7067483 | 0.94 | ABCC8 (0.31) | HTR5AABCC8KCNJ11 | |
| SCHEMBL7071475 | 0.83 | HTR5A (0.35) | HTR5AMEN1KMT2A | |
| SCHEMBL7066216 | 0.83 | HTR5A (0.35) | HTR5A | |
| SCHEMBL7070567 | 0.79 | CHRM4 (0.35) | MEN1KMT2AABCC8KCNJ11 | |
| SCHEMBL7070580 | 0.78 | MEN1 (0.33) | MEN1KMT2ARIPK1KDM4CKMT5B | |
| SCHEMBL7067549 | 0.77 | — | — | |
| SCHEMBL7004764 | 0.75 | ABCC8 (0.31) | ABCC8KCNJ11 | |
| SCHEMBL7000171 | 0.74 | ABCC8 (0.33) | ABCC8KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003105896-A1 | COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | claimed |
| WO-2003045954-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | claimed |
| WO-2003045955-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | claimed |
| WO-2002000222-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | claimed |
| WO-2002000223-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | claimed |
| WO-2003045954-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003045955-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | disclosed |
| US-6225310-B1 | Fused 1,2,4-thiadiazine derivatives, their preparation and use | NOVO NORDISK A/S (DK) | 2001-05-01 | — | — | US | disclosed |